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Abstract
Background: The detection of HIV-1 p24 antigen in diagnostic tests relies on antibodies binding to conserved
areas of the protein to cover the full range of HIV-1 subtypes. Using a panel of 43 different virus-like particles (VLPs)
expressing Gag from clinical HIV-1 isolates, we previously found that some highly sensitive tests completely failed
to detect p24 of certain VLPs, seemingly unrelated to their subtype. Here we aimed to investigate the reason for
this failure, hypothesising that it might be due to single amino acid variations in conserved epitopes.
Methods: Using amino acid alignment, we identified single amino acid variations at position 16 or 170 of p24,
unique to those VLPs that failed to be detected in certain diagnostic tests. Through DNA-mutagenesis, these amino
acids were changed to ones more commonly found at these positions. The impact of these changes on p24
detection was tested in commercial diagnostic tests as well as by Western Blot and ELISA, using epitope-specific
antibodies.
Results and Conclusions: Changing positions 16 or 170 to consensus amino acids restored the detection of p24
by the investigated diagnostic tests as well as by epitope-specific antibodies in Western Blot and ELISA. Hence,
single amino acid changes in conserved epitopes can lead to the failure of p24 detection and thus to false-negative
results. To optimise HIV diagnostic tests, they should also be evaluated using isolates which harbour less-frequent
epitope variants.
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Background
In HIV diagnostics, immunoassays for the detection of
viral capsid protein p24 are employed at the stage of
screening and diagnosis [1]. In the so-called 4th gener-
ation combination screening tests, p24 is used to identify
patients with primary infection, prior to the develop-
ment of anti-HIV antibodies (seroconversion). Technic-
ally, the viral antigen is detected in a sandwich format,
employing antibodies binding to distinct regions of the
protein for capture and detection. These antibodies
should bind to highly conserved regions of the target
protein, thus minimizing the risk of reduced antigen
sensitivity due to subtype-dependent sequence variability
or evolutionary escape, both potentially leading to false-
negative results. Even single amino acid variations can
suffice to decrease the analytical sensitivity of diagnostic
immunoassays, as demonstrated for vaccine-induced
variants of hepatitis B surface antigen [2, 3]. In the case
of HIV, no such diagnostic escape variants have been
described for p24, most likely because they simply go
unnoticed: An acute primary infection would be false-
negative in a 4th generation screening test and thus
not detected unless an HIV RNA nucleic acid test was
performed in parallel, and a chronic infection would be
detected via a patient’s antibody response.
Manufacturers of diagnostic tests evaluate sequence-
associated test sensitivity by testing HIV strains from dif-
ferent subtypes and frequent circulating recombinant
forms (CRFs), thus hoping to cover a range of sequence
variants. However, in a recent study conducted by our
laboratory, using 43 virus-like-particles (VLPs) derived
from clinical HIV-1 isolates expressing the Gag proteins
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of different subtypes and CRFs, we noticed that the failure
of a diagnostic test to detect p24 of certain virus isolates
was not necessarily related to their subtype, as even other-
wise highly sensitive tests failed to detect a common sub-
type B VLP [4]. We hypothesised that detection failure
could be due to subtype-independent amino acid varia-
tions and analysed our p24 sequences in relation to amino
acid variation and detection failure. In this study, we
sought to identify amino acid variations that abrogated
the detection of p24 in diagnostic HIV-1 p24 antigen-only
or 4th-generation HIV screening assays, or by epitope-
specific antibodies used in home-made tests.
Methods
Virus-like particle cloning, production and quantification
VLPs used in this study were expressed from Gag-Pol
encoding eukaryotic expression vectors, which were
cloned for a previous study conducted in our laboratory
[4]. Briefly, the gag-pr region of patient-derived viral
RNA was cloned into the VLP backbone vector of
pCMVΔ8.91, after removing its existing gag-pr portion.
VLPs were produced by transiently transfecting 293 T
cells and VLPs were purified via ultracentrifugation over
a 20 % sucrose cushion. VLP quantification and normalisa-
tion of concentration was based on reverse-transcriptase
(RT) activity (Roche Colorimetric Reverse Transcriptase
Assay, article 11468120910) which was put into relation to
p24 content and international units based on the World
Health Organization p24 reference standard (90/636). One
IU/ml of this standards equals approximately 5.1 pg/ml of
p24 (bioMérieux VIDAS HIV p24 II) and 0.0005 ng/ml of
RT (Roche RT assay) (for more details see [4]).
Sequence alignments
The Los Alamos National Laboratory database (http://
www.hiv.lanl.gov/content/sequence/HIV/mainpage.html)
was queried for all available HIV-1 p24 sequences (of any
subtype). One sequence per patient (option in LANL data-
base) was downloaded in aligned amino acid table format
and the frequency analysis was conducted in Excel.
Mutagenesis
Amino acid changes at position 16 and 170 in p24 were
introduced by side-directed-mutagenesis of the VLP
eukaryotic expression vectors, using the QuickChange II
XL Site-Directed Mutagenesis Kit (200521, Agilent Tech-
nologies). Primers were as follows: pBV8-B-T16S 5’-G
TACATCAGGCCCTATCACCTAGAACTTTAAATG-3’;
pBV59-F2-T16S 5’-GTACATCAGCCTCTATCACCTAG
AACTTTAAATG-3’ ; pBV11-B-S16T 5’-GTACATCAGG
CCATAACACCTAGAACTTTAAATG-3’; pBV43-D-R17
0K 5’-GATTATGTAGATCGGTTCTATAAAACTCTAA
GAGCCGAGC-3’; pBV60-D-R170K 5’-GATCGGTTCT
ATAAAACTCTAAGAGCC-3’; pBV42-12BF-N170K 5’-
GACAGGTTCTTTAAGACCCTAAGAGCC-3’; pBV38-
D-K170R 5’-GACTATGTAGATCGGTTCTATAGAACT
CTAAGAGCCGAGC-3’. Mutagenesis was verified by se-
quencing (for sequencing primers see [4]).
Diagnostic tests
VLPs were diluted to 10 IU/ml p24 antigen (or 0.005 ng/
ml RT) in negative human plasma (Swiss Red Cross Blood
Donation Centre Zurich) in a single batch per VLP and
stored at −20 °C. Antigen reactivity of the (anti-HIV-nega-
tive) samples was analysed with the following CE-marked
and FDA-approved diagnostic tests and platforms: Abbott
Architect HIV Ag/Ab Combo; bioMérieux VIDAS HIV
p24 II; Siemens Enzygnost Integral II; Siemens Enzygnost
Integral 4.
Western blot
VLPs in PBS were diluted in NuPage LDS sample buffer
and reducing agent (NP0007 and NP0009, Life Technolo-
gies) to a final concentration of 10 ng/ml RT. Samples
were heated for 10 min at 95 °C. SDS polyacrylamide gel
electrophoresis was performed using 10 % gels in standard
Tris/Glycine buffer, and proteins were blotted on nitrocel-
lulose membrane by wet transfer over night. Primary
mouse monoclonal antibodies used to detect HIV p24
were AG3.0 (4121, NIH AIDS Reagent Program) and
YDHIV1gp24 (sc-73300, Santa Cruz). Polyclonal human
anti-p24 plasma was obtained by pooling plasma from 10
HIV-positive individuals, inactivated with 0.5 % Triton X-
100. Species-specific HRP-coupled secondary antibodies
were obtained from KPL (goat-anti-mouse HRP 474–
1806; goat-anti-human HRP 141–992). Super Signal West
Pico (34077, Thermo Scientific) was used as chemilumin-
escent substrate and the reaction visualised in the Image-
Quant LAS-4000 imager (GE Healthcare).
VLP-ELISA
VLPs in PBS were lysed in 3x SNCR virus disruption
buffer [5] and coated onto clear 384-well plates (Nunc
MaxiSorb P6366, Sigma Aldrich) at a concentration of
5 ng/ml RT over night at 4 °C. After blocking with 2 %
non-fat milk in PBS, primary and secondary antibodies
(see Western Blot) were sequentially applied for 1 h with
intermittent washes. TMB liquid substrate (T8665, Sigma
Aldrich) was diluted at 1:2 in H2O and added for 15 min,
followed by the addition of 1 M H2SO4 to stop the reac-
tion. Optical density was measured at 450 nm on the
Perkin Elmer EnVision microplate reader. Cut-off values
were derived from wells mock-coated with the same re-
agent, but lacking antigen, and processed in the same way.
Ethical approval
This study did not use any personal information, but
only previously published viral sequences [4]. Therefore,
Vetter et al. BMC Infectious Diseases  (2015) 15:468 Page 2 of 8
in full accordance with Swiss legislation (Federal Act on
Data Protection of 19 June 1992; see https://www.admin.
ch/opc/en/classified-compilation/19920153/index.html)
informed consent was not necessary.
Results
Amino acid variants
To identify amino acid variations which might be respon-
sible for the failure to detect p24 in a diagnostic test, the
p24 sequences of all 43 VLP panel members investigated
in our previous study were aligned (sequences available at
NCBI GenBank accession numbers KJ689249-KJ689290)
[4]. This highlighted a single amino acid variation of
Serine (S) to Threonine (T) at position 16 of pBV8-B and
pBV59-F2; both VLPs had been the only ones poorly de-
tected in two highly sensitive tests in our previous study
(Siemens Enzygnost Integral 4 and Innogenetics Innotest
HIV Antigen mAb). Furthermore, we identified a variation
of Lysine (K) to Arginine (R) or Asparagine (N) at position
170, which might be accountable for the failure of the
bioMérieux VIDAS DuoUltra and VIDAS HIV p24 II to
detect VLPs pBV43-D, pBV60-D and pBV42-12BF. To en-
sure that amino acid variations in the Gag VLPs were not
erroneously introduced during the Gag cloning procedure
[4], the relevant part of the original viral RNA isolated
from patient plasma was sequenced, and the amino acid
variations at position 16 and 170 of the respective VLPs
were confirmed at nucleotide level in the viral genome
(data not shown).
In order to assess the frequency of the S16T and
K170R/N variants in naturally occurring HIV-1 isolates,
all available p24 sequences were downloaded from the Los
Alamos National Laboratory database (http://www.hiv.
lanl.gov/content/sequence/HIV/mainpage.html). Table 1
lists the total number of intact sequences at positions 16
and 170 and the frequency of amino acids at these posi-
tions grouped by common HIV-1 subtypes and CRFs. At
position 16, 97.7 % (10’125) of all sequences had an S
present. The second most common amino acid at this
position was a T (174, 1.68 %), followed by A (62, 0.6 %).
Interestingly, all of the 9 available HIV-1 group N se-
quences had a T at position 16. At position 170, 97.85 %
(10’142) of all sequences had a K present. R accounted for
the large majority of other amino acids at this position
(216, 2.08), and an N was only found in three sequences
(0.03 %).
To investigate the impact of these amino acid varia-
tions on p24 detectability, we introduced a T16S change
into pBV8-B and pBV59-F2, as well as an R170K change
into pBV43-D and pBV60-D and an N170K change into
pBV42-12BF. As control, we also introduced an S16T
change into pBV11-B and K170R into pBV38-D, both
VLPs having been detected well by all diagnostic tests
previously investigated [4]. Table 2 summarises amino
acids found in the “wildtype” VLPs as cloned from virus
isolates, and changes introduced to investigate the im-
pact of these amino acid variants on p24 detection, as
described in the subsequent sections.
Diagnostic tests
All wildtype and mutant VLPs were diluted to 10 IU/ml
p24 in HIV-negative human plasma and analysed using
HIV diagnostic tests that had failed to detect the wild-
type VLP variants (see Table 2). As control, these VLP
preparations were also tested on the Abbott Architect
HIV Ag/Ab Combo to confirm the presence of p24. As
previously observed, the pBV8-B and pBV59-F2 wildtype
VLPs were not detected by the Siemens Enzygnost In-
tegral II and 4 at 10 IU/ml, whereas the positive con-
trol, wildtype pBV11-B, was detected well by both tests
(Fig. 1a, b). In contrast, with the T16S mutation intro-
duced, pBV8-B-T16S and pBV59-F2-T16S were both de-
tected as well as pBV11-B, while the mutated control VLP
pBV11-B-S16T was no longer detectable. The Abbott
Architect yielded good S/Co ratios for all tested VLPs,
confirming the presence of p24 in these samples (panel
C). These results suggest a crucial role for the amino acid
found at position 16 for the detection of p24 by the
Siemens Enzygnost Integral II and 4.
Similarly, analysis of the position 170 wildtype and
mutant VLPs on the bioMérieux VIDAS p24 II (Fig. 1d)
showed a restored ability to detect the mutant pBV43-
D-R170K, pBV60-D-R170K and pBV42-12BF-N170K.
Introducing the amino acid variant (R) at position 170
into the wildtype pBV38-D, reduced, but not completely
abolished, detection by the bioMérieux VIDAS HIV p24
II. The somewhat lower re-gained detectability of
pBV43-D-R170K and pBV60-D-R170K and the only
two-fold (rather than complete) loss off pBV38-D-
K170R signal suggest that additional, unidentified epi-
tope variations in these VLPs also play a role in detec-
tion by this test. Again, all VLPs were also tested on the
Abbott Architect to control for the presence of viral
antigen (panel E). These observations demonstrate that a
single amino acid variation can account for the complete
failure of p24 antigen detection by certain diagnostic
HIV-1 tests.
Western blot and ELISA
To further confirm the role of these single amino acid
variations on antibody binding, the wildtype and mutant
VLPs were analysed by Western Blot, using primary
antibodies binding to the epitope-regions in question.
The epitope of the antibody AG3.0 was mapped to the
highly conserved motive SPRTLNA (position 16–22 in
p24) [6] and antibody YDHIV1gp24 was largely mapped
to amino acids 148–197 [7]. Figure 2 illustrates the in-
ability of the respective antibodies to detect wildtype
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Table 1 Frequency of amino acid variations for positions 16 and 170 of p24 of sequences deposited in the Los Alamos National Laboratory sequence database
Subtypes Amino acids at position 16 Amino acids at position 170
S T A H L M Y Q Total K R N E I T Y Total
A (A1/A2) 330 6 2 1 339 334 3 1 1 339
97.35 % 1.77 % 0.59 % 0.29 % 98.53 % 0.88 % 0.29 % 0.29 %
B 4′387 78 45 1 1 4′512 4′412 112 4′525
97.23 % 1.73 % 1.00 % 0.02 % 0.02 % 97.50 % 2.48 % 1
C 2′369 50 11 2 1 2′433 2′357 68 1 2′426
97.37 % 2.06 % 0.45 % 0.08 % 0.04 % 97.16 % 2.80 % 0.04 %
D 123 5 128 126 1 127
96.09 % 3.91 % 99.21 % 0.79 %
F (F1/F2) 85 2 87 77 6 1 84
97.70 % 2.30 % 91.67 % 7.14 % 1.19 %
G 65 1 66 64 64
98.48 % 1.52 % 100.00 %
CRF01_AE 1′015 1 1 1′017 1′012 4 1′016
99.80 % 0.10 % 0.10 % 99.61 % 0.39 %
CRF02_AG 97 1 98 96 2 98
98.98 % 1.02 % 97.96 % 2.04 %
CRF07_BC 140 140 139 139
100.00 % 100.00 %
Other group M 1′456 20 3 1′479 1′457 20 1 1′478
98.44 % 1.35 % 0.20 % 98.58 % 1.35 % 0.07 %
Group O 20 9 20 20
100.00 % 100.00 %
Group N 9 20 8 1 9
100.00 % 88.89 % 11.11 %
Group P 2 2 2 2
100.00 % 100.00 %
Unclassified 36 2 38 38 38
94.74 % 5.26 % 100.00 %
Total 10′125 174 62 2 2 1 1 1 10′368 10′142 216 3 1 1 1 1 10′365
97.66 % 1.68 % 0.60 % 0.02 % 0.02 % 0.01 % 0.01 % 0.01 % 97.85 % 2.08 % 0.03 % 0.01 % 0.01 % 0.01 % 0.01 %
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VLPs with the rare amino acids in the critical position
and the restored detection upon mutation of these
amino acids to the consensus sequences. Furthermore,
introducing the amino acid variant into the consensus
background abolished p24 detection of these VLPs
(pBV11-B for AG3.0 and pBV38-D for YDHIV1gp24).
On a parallel Western blot loaded with VLPs from the
same sample preparation, p24 was detected using pooled
plasma of HIV-1+ individuals, confirming the presence
of p24 in all samples.
In addition, we also tested the antibodies’ ability to
detect p24 directly coated onto ELISA plates after VLP
Table 2 Summary of VLPs investigated in this study
VLP Accession number AA position in p24 (Gag)a AA in wt VLP AA change introduced HIV diagnostic test with low sensitivity for wt
pBV8-B KJ689249 16 (148) T S Siemens Enzygnost Integral II/4
pBV59-F2 KJ689286 16 (148) T S Siemens Enzygnost Integral II/4
pBV11-B KJ689251 16 (148) S T N/A – control VLP
pBV43-D KJ689277 170 (302) R K bioMérieux VIDAS HIVp24 II
pBV60-D KJ689287 170 (302) R K bioMérieux VIDAS HIVp24 II
pBV42-12BF KJ689276 170 (302) N K bioMérieux VIDAS HIVp24 II
pBV38-D KJ689274 170 (302) K R N/A – control VLP
AA amino acid, wt wildtype, N/A not applicable as these VLPs were used as controls
ain HXB2 reference sequence; accession number in NCBI GenBank
Fig. 1 Detection of wildtype and mutated VLPs by diagnostic tests. VLPs were diluted to 10 IU/ml in negative human plasma and analysed with
the indicated diagnostic tests. Panels a, b and d show antigen detection results of wildtype (wt) and mutated VLPs for those diagnostic tests
which failed to detect wildtype VLPs harbouring the S16T (a and b) or K170R/N variant (d). Panels c and e show results of antigen detection by
the Abbott Architect HIV Ag/Ab Combo to control for the presence of p24 antigen. Lines indicate S/Co = 1, which represents the lower limit of
S/Co ratios for unequivocally positive samples according to the manufacturer’s instructions. In case of the bioMérieux VIDAS HIV p24 II the line
indicates 3 pg/ml, denoting the lower limit of the quantifiable range for this test
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lysis. Figure 3 panels a and c show a reduced signal-to-
cut-off (S/Co) ratio for the detection of the aberrant
wildtype VLPs compared to VLPs mutated to the con-
sensus sequence, and good detection of the control wild-
type VLPs (pBV11-B and pBV38-D) compared to the
matching mutated ones. All VLPs were also detected
with HIV-1+ pooled plasma to control for the presence
of p24 on the coated plates (panels B and C). Due to the
high variability and background of this direct ELISA, re-
sults are not as clear-cut as for the Western blot, but
Fig. 2 Detection of wildtype and mutated VLPs by western blot with epitope-specific antibodies. Position 16 and 170 wildtype and mutated VLPs were
detected with the epitope-specific antibody AG3.0 (a) and YDHIV1gp24 (b), respectively. In parallel, the same sample preparations were loaded on a
second gel and p24 was detected with pooled HIV+ plasma on the membranes to control for the presence antigen (a and b lower panels)
Fig. 3 Detection of wildtype and mutated VLPs by ELISA with epitope-specific antibodies. Equal amounts of VLPs were lysed, directly coated on
ELISA plates and detected either with epitope-specific antibodies (a: AG3.0 for position 16; c: YDHIV1pg24 for position 170) or pooled HIV+ plasma
to control for the presence of antigen (b and d). S/Co ratios were calculated in relation to background signals of the respective antibodies on
uncoated wells. Results are averages of three experiments. Lines indicate S/Co =1, above which samples were scored as detectable
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they nevertheless support the observation that the inves-
tigated single amino acid variations can influence anti-
body binding to p24.
Discussion
Modern HIV 4th generation combination screening tests
or antigen-only tests employed for HIV screening and
diagnosis, are expected to detect all HIV-1 subtypes and
circulating recombinant forms. Many of these tests cur-
rently on the market indeed have a fairly good sensitivity
and subtype breadth [4, 8]. We were thus surprised that
some otherwise highly sensitive tests failed to detect
certain VLPs at a p24 concentration of 10 IU/ml, which
roughly corresponds to 500’000 cp/ml RNA (for conver-
sion see [4]). The analyses conducted in the present
study suggest that this failure is not necessarily due to a
set of subtype-specific amino acid sequence variations,
but rather due to single amino acid variations. The
amino acids at position 16 and 170 identified here as be-
ing responsible for detection failure, are both located in
highly conserved regions of p24 and deviations from the
consensus sequence are of conservative nature. Although
position 16 is part of the well-studied HLA-B*57-re-
stricted CTL epitope ISW9 [9] and hence target of select-
ive pressure, escape variants have only been described for
positions 14 and 15 [10, 11]. It’s role might be rather of
structural nature, as position 16 is part of an N-terminal
three amino acid linker-region (14–16) in p24 [12], which
plays a role in protein re-folding upon proteolytic pro-
cessing of Gag [13]. Position 170 is part of the major
homology region (MHR) of p24 (153–172), the most con-
served part of the viral capsid found in many retroviruses,
with an essential role in Gag assembly [14, 15] and viral
infectivity [16]. The rather conservative nature of the K to
R variant and the relative low frequency of less conser-
vative substitutions at position 170 are in line with the im-
portance of conserving the MHR function. An Alanine
exchange at K170 was found to maintain assembly func-
tion but not infectivity of viral particles [16, 17]. Notably,
a certain degree of flexibility seems to exist, given the K to
N change (relatively large positive to smaller uncharged
properties) observed in pBV42-12BF. It is unknown if this
requires compensatory second-site changes in the protein.
The frequency of S16T and K170R variations found in
the LANL deposited sequences, suggests that as many as
1:50–1:60 patients carry these variations. While it is not
known how frequent they are in primary infection, their
importance in the use of immunoassays should be kept
in mind when selecting epitope regions for generation of
antibodies for diagnostic tests. Our previous study sug-
gests that aside from the Siemens Enzygnost Integral II
and 4, the Innotest HIV Antigen mAb from Innogenetics
also targets position 16. Here too, pBV8-B and pBV59-
F2 were the only VLPs of the whole panel to be poorly
detected [4]. Furthermore, in addition to the bioMérieux
4th generation combo test (DuoULTRA) and antigen-
only test (HIV p24 II), the Siemens ADVIA CHIV also
had poor sensitivity for pBV43-D, pBV60-D and pBV42-
12BF, indicating binding of antigen around position 170
in this test. Notably, the bioMérieux tests detected sev-
eral VLPs with severely lower sensitivity [4], but obvious
amino acid variations could only be identified for the
three VLPs carrying the position 170 amino acid variant.
This suggests that other epitopes targeted by this test
are also sensitive to sequence variation.
Conclusion
Although both amino acid variations described in this
study are of rather conservative nature, their impact on
antibody binding and detection of p24 by diagnostic
HIV tests is striking. It demonstrates that test sensitivity
and breadth of detection are not only defined by sub-
types and their associated overall sequence variations,
but also by single amino acid polymorphisms. Future
antigen test development should take these findings into
account to cover the broadest spectrum of circulating
isolates possible.
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